Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapies for cancer and chronic degenerative diseases. Key programs include imetelstat (a telomerase inhibitor for oncology), GRN1005 (a peptide-conjugated taxane for brain metastases), and GRNOPC1 (a human embryonic stem cell-derived therapy for spinal cord injury).
Key Financial Metrics
| Metric (in thousands) | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $1,505 | $918 |
| Net Loss | $(24,389) | $(16,640) |
| Net Loss Per Share (Basic & Diluted) | $(0.20) | $(0.18) |
| Operating Expenses | $25,861 | $17,395 |
| Research & Development (R&D) | $16,755 | $13,545 |
| General & Administrative (G&A) | $9,106 | $3,850 |
| Cash and Cash Equivalents | $35,412 | $35,900 |
| Total Cash, Restricted Cash & Marketable Securities | $207,300 | $221,300 |
| Accumulated Deficit | $(713,039) | $(688,650) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 64% to $1.5 million, driven primarily by a rise in license fees and royalties ($1.36 million vs. $0.69 million in Q1 2010). Collaborative agreement revenue decreased slightly to $0.15 million.
- Increased Net Loss: Net loss widened by approximately $7.7 million (46% increase) to $24.4 million. This was primarily due to higher clinical trial costs, increased drug manufacturing expenses, and significant non-cash stock-based compensation.
- R&D Expenses: Increased by $3.2 million to $16.8 million. Drivers included the start-up and enrollment of four Phase 2 trials for imetelstat and one Phase 1 trial for GRNOPC1, plus $0.6 million in acquired in-process R&D expense related to the Angiochem license.
- G&A Expenses: Surged by $5.3 million to $9.1 million. The primary driver was a $3.5 million non-cash stock-based compensation charge associated with the separation agreement and equity modification for former CEO Thomas B. Okarma.
- Liquidity: Total liquid assets (cash, restricted cash, and marketable securities) decreased by $14 million to $207.3 million, reflecting cash burn from operations.
Guidance, Outlook, and Risks
- Capital Resources: Management estimates existing capital resources and interest income are sufficient to fund operations through at least December 2012. However, substantial additional capital will be required for future clinical development.
- Clinical Pipeline:
- Imetelstat: Four Phase 2 trials are open for enrollment (NSCLC, Breast Cancer, Multiple Myeloma, Essential Thrombocythemia).
- GRN1005: Phase 2 trial for brain metastases planned to open in the second half of 2011.
- GRNOPC1: Phase 1 trial for spinal cord injury is open with five clinical sites.
- Key Risks:
- Regulatory & Clinical: Uncertainty regarding FDA approval timelines and clinical trial results. The company has no experience conducting large-scale late-stage trials.
- Intellectual Property: Ongoing patent oppositions in Europe regarding hESC technologies and interference proceedings in the U.S. regarding endoderm cells.
- Stem Cell Policy: Potential impact of government restrictions or political commentary on the use of human embryonic stem cells (hESCs).
- Legal: Recent securities class action and derivative lawsuits were voluntarily dismissed without prejudice in early 2011.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $12.7 million quarterly operating cash burn against the $207 million liquid asset base.
- Angiochem Transaction: Review the terms of the January 2011 license agreement and the issuance of 5.26 million shares to Angiochem as consideration.
- CEO Separation Costs: Confirm the impact of the $3.5 million non-cash charge related to the former CEO's separation on future G&A expenses.
- Clinical Enrollment: Monitor patient enrollment rates for the four imetelstat Phase 2 trials and the GRNOPC1 Phase 1 trial.
- Patent Status: Track the outcome of the European Patent Office (EPO) oppositions regarding hESC patents and the U.S. interference proceeding with ViaCyte.